Intezyne has assembled a world-class Clinical Advisory Board to provide guidance and insight into the best clinical practices for treating patients with cancer. David Paul Kelsen, M.D., will chair the committee that includes David B. Solit, M.D., and Matthew H. Kulke, M.D. Amy S. Lee, Ph.D., the leading expert in GRP78 proteins, is serving as Advisor/Collaborator.


David Paul Kelsen, M.D.

Edward S. Gordon Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center

Dr. Kelsen is a board-certified medical oncologist with clinical and research interests in the field of gastrointestinal malignancies, neuroendocrine tumors, and cancers of unknown primary origin. He is a physician on the Gastrointestinal Oncology Service, which he led as Chief from 1991 to 2011, and serves on MSK’s Research Council. Dr. Kelsen’s research has been supported by grants from the National Cancer Institute, the American Cancer Society, and the Lustgarten Foundation. Dr. Kelsen has served as a member of the Oncology Drug Advisory Committee of the U.S. Food and Drug Administration, the GI Committee of the Radiation Therapy Oncology Group, and the Investigational Drugs Steering Committee of the Cancer Therapy Evaluation Program of the National Cancer Institute. He currently serves as co-Chair of the Clinical Trials subcommittee of the Lustgarten Foundation for Pancreatic Cancer Research. Dr. Kelsen received his Doctor of Medicine from Hahnemann University School of Medicine (Philadelphia), conducted his residency at Temple University Hospital and his fellowship at Memorial Sloan Kettering.


Matthew H. Kulke, M.D.

Program in Neuroendocrine and Carcinoid Tumors at the Dana-Farber Cancer Institute and Associate Profession of Medicine, Harvard Medical School

Dr. Kulke has led numerous clinical and translational studies in patients with gastrointestinal malignancies and neuroendocrine tumors. He has served as study chair for a national study of pancreatic cancer therapies performed by the Cancer and Leukemia group B and funded by the National Cancer Institute. His current efforts have focused on clinical and translational research in carcinoid and pancreatic neuroendocrine tumors. Dr. Kulke is the recipient of the George Canellos Award for Clinical Investigation and the Ruth Brufsky Award for Pancreatic Cancer Research. He serves on the advisory board for the European Neuroendocrine Tumor Society, the executive committee of the North American Neuroendocrine Tumor Society, and is chair of the Neuroendocrine Tumor Task force for the National Cancer Institute. Dr. Kulke received his Doctorate in Medicine from the University of California, San Francisco School of Medicine, completed an internship and residency in internal medicine at Brigham and Women's Hospital and his fellowship in medical oncology at Dana-Farber. Dr. Kulke also has received a Master’s Degree in medical science from Harvard Medical School. 


David B. Solit, M.D.

Geoffrey Beene Chair and Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering

As a member of the Genitourinary Oncology Service, Dr. Solit specializes in treating cancers of the prostate, bladder, kidney, testis, and other related cancers. He is very involved in clinical trials, particularly those of targeted drugs known as kinase inhibitors, which block pathways inside cancer cells that cause the cells to grow or spread. Dr. Solit’s laboratory in the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering completed the first whole-genome analysis of a patient with bladder cancer who had a complete and durable response to a novel targeted drug that was effective in only a small minority of patients. This analysis determined what was genetically unique about this patient’s tumor, and the group is testing the same drug in other patients whose tumors have a similar genetic profile. As the Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO), Dr. Solit leads a multidisciplinary team of clinicians, geneticists, bioinformaticians, and laboratory scientists. The mission of the CMO is to integrate molecular and clinical information to develop therapies that are individualized to each patient’s cancer. Dr. Solit received his Doctor of Medicine from the University of Pennsylvania School of Medicine, conducted his residency at Barnes Jewish Hospital/Washington University School of Medicine in St. Louis, and completed his fellowship at Memorial Sloan Kettering.